Executive Summary
This period reveals $4.27B in 15 new federal contract obligations, all bullish signals, providing long-term revenue backlogs through 2041, with Leidos entities capturing ~30% ($1.27B obligated, $7.9B potential). Concentrations in IT/engineering (44% of value), construction (14%), and health/defense R&D highlight sustained federal spending priorities. Institutional investors should prioritize Leidos Holdings (LDOS) and Huntington Ingalls (HII) for backlog growth, while monitoring small/mid-cap winners like Kratos S2 and Remote Medicine for outsized upside from options exercises.
Tracking the trend? Catch up on the prior New Federal Contractors digest from February 06, 2026.
Investment Signals(4)
- Leidos dominates with $1.27B obligated across aviation, biomed, and engineering(HIGH)▲
Three contracts total $1.27B obligated (up to $7.9B base+options) through 2041, signaling multi-decade backlog stability for parent Leidos Holdings.
- HII secures $493M GSA engineering order with $1.32B ceiling(HIGH)▲
Zero outlay yet but full options potential through 2030 underscores revenue ramp-up for Huntington Ingalls in federal technical services.
- Brasfield & Gorrie locks $382M in GSA construction projects(MEDIUM)▲
Two firm fixed price awards total $382M obligated through 2029, advancing federal infrastructure modernization backlog.
- Small/mid-caps claim 45% of value in IT/defense/health(MEDIUM)▲
Firms like Remote Medicine ($484M), Kratos S2 ($338M), and Synergy ($273M) win via set-asides/SBIR, offering high-beta federal exposure.
Risk Flags(4)
- Execution[HIGH RISK]▼
Long performance periods (avg. 5+ years to 2041) expose to delays/tech obsolescence across 93% of contracts.
- Execution[HIGH RISK]▼
Firm fixed price in 40% of value ($1.7B) risks cost overruns, esp. construction/remediation at remote sites.
- Execution[MEDIUM RISK]▼
Subaward dependencies average 20-37% of obligations in 60% of contracts, with peaks at $275M (Kratos).
- Market[MEDIUM RISK]▼
Zero/low outlays in new awards (e.g., HII $0, Leidos Biomed $24M) signal funding delays amid FY26 budget uncertainty.
Opportunities(3)
- ◆
$1.9B+ in unexercised options across contracts (e.g., Leidos ERAM $6B potential, HII $860M) to unlock via government exercises.
- ◆
Extensions to 2027-2041 in 80% of contracts could add 1-2 years revenue, esp. FAA/ERAM and GSA engineering.
- ◆
Small/mid-cap winners (e.g., Remote Medicine $77M options, Alvarez $101M) offer M&A targets or high-beta plays in health/IT.
Sector Themes(3)
- ◆
47% of value ($2B) in NAICS 5415xx for ERAM, enterprise apps, LAN/IRPs through 2029, led by Leidos/Synergy.
- ◆
19% ($800M) in NAICS 236/237 for ports, campuses, pipelines through 2029, with Brasfield/HC Beck advancing.
- ◆
22% ($950M) in biomed/HIV kits/space polarimetry to 2026-2041, via Leidos Biomed/Remote/BAE.
Watch List(4)
- 👁
{"entity"=>"Leidos Holdings (LDOS)", "reason"=>"30% value capture with $7.9B long-term ceiling; track backlog accretion.", "trigger"=>"Q1 FY26 earnings: ERAM options exercised >$500M"}
- 👁
{"entity"=>"Huntington Ingalls (HII)", "reason"=>"$1.32B ceiling at $0 outlay signals near-term ramp potential.", "trigger"=>"Outlays exceed $100M in 6 months"}
- 👁
{"entity"=>"Kratos S2 Inc.", "reason"=>"Woman-owned SBIR III $466M defense R&D with heavy subawards.", "trigger"=>"Subaward resolutions or commercialization news"}
- 👁
{"entity"=>"Remote Medicine Inc.", "reason"=>"$484M USAID HIV kits to 2026 as small biz outlier.", "trigger"=>"Options exercised or global health funding boost"}
Get daily alerts with 4 investment signals, 4 risk alerts, 3 opportunities and full AI analysis of all 15 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC